Table 2.

Outcomes of R/R MCL after brexu-cel failure according to salvage therapy

Len/R2CT/ICTBTKi/VenTCEOther targeted therapyRadiation
Response rate       
ORR, n (%) 3 (18.8%) 3 (23.1%) 3 (42.9%) 1 (50%) 
CR, n (%) 3 (18.8%) 2 (15.4%) 3 (42.9%) 1 (50%) 
PR, n (%) 1 (7.7%) 
PFS       
Median (95% CI), mo 2 (0.7-4.4) 1.1 (0.7-7.5) 1.7 (1.1-3.1) 1.5 (0.9-NA) 2.7 (2.4-NA) NR (2.4-NR) 
6 months (95% CI), % 23.4 (5.7-47.9) 30.8 (9.5-55.4) 42.9 (9.8-73.4) 50 (0.6-91) 
12 months (95% CI), % 15.6 (2.5-39.1) 23.1 (5.6-47.5) 42.9 (9.8-73.4) 50 (0.6-91) 
OS       
Median (95% CI), mo 6.7 (2- NA) 5.8 (1.5-NA) 2.8 (1.4-4) NR (3.3-NA) 9.6 (7.7-NA) 11.3 (NA-NA) 
6 months (95% CI), % 44.9 (17.7-69) 56.3 (27.2-77.6) 71.4 (25.8-92) 100 (NA-NA) 
12 months (95% CI), % 36.2 (10.8-62.8) 35.9 (11.7-61.3) 57.1 (17.2-83.7) 
Len/R2CT/ICTBTKi/VenTCEOther targeted therapyRadiation
Response rate       
ORR, n (%) 3 (18.8%) 3 (23.1%) 3 (42.9%) 1 (50%) 
CR, n (%) 3 (18.8%) 2 (15.4%) 3 (42.9%) 1 (50%) 
PR, n (%) 1 (7.7%) 
PFS       
Median (95% CI), mo 2 (0.7-4.4) 1.1 (0.7-7.5) 1.7 (1.1-3.1) 1.5 (0.9-NA) 2.7 (2.4-NA) NR (2.4-NR) 
6 months (95% CI), % 23.4 (5.7-47.9) 30.8 (9.5-55.4) 42.9 (9.8-73.4) 50 (0.6-91) 
12 months (95% CI), % 15.6 (2.5-39.1) 23.1 (5.6-47.5) 42.9 (9.8-73.4) 50 (0.6-91) 
OS       
Median (95% CI), mo 6.7 (2- NA) 5.8 (1.5-NA) 2.8 (1.4-4) NR (3.3-NA) 9.6 (7.7-NA) 11.3 (NA-NA) 
6 months (95% CI), % 44.9 (17.7-69) 56.3 (27.2-77.6) 71.4 (25.8-92) 100 (NA-NA) 
12 months (95% CI), % 36.2 (10.8-62.8) 35.9 (11.7-61.3) 57.1 (17.2-83.7) 

N, number; NA, not applicable; NR, not reached.

or Create an Account

Close Modal
Close Modal